Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Complement, coagulation and FcRn antibodies act on plasma protein cascades and on recycling of immunoglobulin G (IgG). Eculizumab, ravulizumab and pozelimab bind complement component C5 and block formation of the membrane attack complex. Sutimlimab inhibits C1s, the serine protease that initiates the classical complement pathway. Emicizumab bridges activated factor IX and factor X, while concizumab and marstacimab bind tissue factor pathway inhibitor (TFPI). Nipocalimab and rozanolixizumab block the neonatal Fc receptor (FcRn) and are used to study IgG half-life and clearance.
Synonyms: M281
Nipocalimab is a fully human, recombinant IgG1 monoclonal antibody engineered to lack Fc glycosylation. It binds with high affinity to the neonatal Fc receptor (FcRn), blocking the recycling and transcytosis of IgG. Nipocalimab is used in research on IgG-mediated autoimmune diseases, including hemolytic disease of the fetus and newborn (HDFN) and myasthenia gravis.
Synonyms: BI 655075
Idarucizumab is a humanized monoclonal antibody fragment designed as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, facilitating the restoration of hemostasis. This targeted mechanism of action makes Idarucizumab essential for research in anticoagulation reversal and therapeutic management.
Claseprubart is a monoclonal antibody designed to specifically target and bind to human complement C1s. By binding to this key component of the complement system, Claseprubart effectively inhibits its activation, thereby exerting immunosuppressive effects. This antibody is particularly valuable in research focused on autoimmune and inflammation-related diseases, offering potential insights into the mechanisms of immune regulation and pathological inflammation.
The Anti-CD59 Antibody is a humanized antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD59. This antibody is comprised of a muIgG1 type heavy chain and a huκ type light chain, with an estimated molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the role of CD59 in immune regulation and disease pathogenesis.
The Anti-vWF Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target von Willebrand Factor (vWF). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145.62 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control, ensuring accurate and reliable results in research applications.
Synonyms: JNJ-375; JNJ-64179375; JNJ-9375
Ichorcumab (JNJ-375) is a fully human monoclonal antibody of the IgG4 subclass, specifically designed to target thrombin. This antibody selectively binds to exosite 1 on thrombin, effectively inhibiting substrate binding while preserving the enzyme's catalytic activity. For experimental controls, the recommended isotype control is Human IgG4 (S228P) kappa.
Morolimumab is a humanized IgG1 monoclonal antibody that specifically targets the RHD antigen, also known as CD240D. This antibody is designed for use in the study of immune-related disorders, providing a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for these conditions.
Synonyms: ALXN-1720
Gefurulimab (ALXN-1720) is a bispecific human-derived antibody designed to target complement component C5 and albumin. This antibody binds specifically to C5, effectively inhibiting its activation. The dual targeting mechanism allows for enhanced circulation time and improved pharmacokinetic profile, making it a valuable tool for research in immune response and complement system disorders.
Synonyms: LFB-R593
Roledumab (LFB-R593) is a human IgG1-κ monoclonal antibody that specifically targets the RHD antigen, also known as CD240D. This antibody is produced in YB2/0 rat hybridoma cells, ensuring high specificity and affinity for its antigen. Roledumab is utilized primarily in research focused on RhD antigen expression and its immunological implications, making it a valuable tool in studies related to blood typing, Rh disease, and other hematological disorders.
Tanruprubart is a monoclonal antibody engineered to target human complement C1q. This antibody binds specifically to C1q, effectively inhibiting the initiation of the classical complement activation pathway. By blocking this pathway, Tanruprubart demonstrates significant immunosuppressive properties, making it an invaluable tool for research into autoimmune and inflammation-related diseases. Its precise targeting offers potential for detailed studies on the role of complement activation in pathological conditions.
Sutacimig is a humanized antibody designed to target coagulation factor 7 and TREML1. This antibody features the (H-γ4_L-κ)_(H-γ4_L-κ) isotype configuration, optimizing its specificity and functional activity in therapeutic applications. Sutacimig is primarily utilized in research focused on the modulation of blood coagulation pathways and immune response mechanisms, making it a valuable tool for studies in hematology and immunology.
The Anti-F8/Factor VIII Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets human coagulation Factor VIII (F8), a key protein in the blood clotting cascade. This antibody features a human IgG4 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on hematology, coagulation disorders, and therapeutic antibody development.
NGM-621 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Complement C3, a critical component of the complement system involved in immune responses. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 149.04 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.
Synonyms: UCB7665
Rozanolixizumab (UCB7665) is a humanized, high-affinity monoclonal antibody targeting the human neonatal Fc receptor (FcRn). Classified as an IgG4P isotype, this antibody is primarily utilized in research focused on the reduction of pathogenic IgG in various autoimmune and alloimmune disorders. Its specific interaction with FcRn highlights its potential for modulating immune responses and antibody recycling, making it a valuable tool for studies in immunology and therapeutic development.
Cenvacibart is a monoclonal antibody designed to inhibit coagulation factor XI (F11), a key protein in the coagulation cascade. By targeting and blocking the activity of factor XI, Cenvacibart effectively reduces thrombus formation. This antibody is particularly valuable in the study of thrombotic disorders, offering a promising tool for researchers exploring the mechanisms and potential treatments of these conditions.
Emicizumab is a bispecific monoclonal antibody designed to mimic the function of activated factor VIII by bridging activated factor IX and factor X, effectively restoring hemostasis. This antibody is utilized primarily in research focused on hemophilia A, offering a novel approach to studying and potentially managing this bleeding disorder.
Synonyms: Anti-Human C5; Humanized Antibody
Eculizumab is a long-acting, humanized monoclonal antibody that specifically targets complement component C5. By inhibiting the cleavage of C5 into C5a and C5b, Eculizumab effectively prevents the activation of the terminal complement system, including the formation of the membrane attack complex (MAC). This antibody is particularly useful in research focused on hemolysis and other conditions related to complement system dysregulation.
Synonyms: SYNT001; ALXN1830
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting the interaction between FcRn and the Fc portion of IgG molecules, Orilanolimab effectively impedes the activation of immune complexes (IC) mediated by FcRn. This action disrupts key pathways involved in IgG homeostasis, as well as innate and adaptive immune responses. This antibody is pivotal for research focused on the modulation of immune functions and the therapeutic regulation of antibody-mediated diseases.
Synonyms: SAR 445088
Riliprubart (SAR445088) is a humanized monoclonal antibody targeting C1s, a critical enzyme in the proximal segment of the classical complement pathway. This antibody selectively binds to activated C1s, effectively preventing its enzymatic activity on substrates C4 and C2. By inhibiting these interactions, Riliprubart impedes the formation of the classical pathway C3 convertase, C4b2a, thus modulating the immune response. This specific inhibition mechanism makes Riliprubart a valuable tool for research into immune regulation and the pathophysiology of diseases mediated by the classical complement system.
Synonyms: HBM9161; IMVT-1401
Batoclimab is a fully humanized IgG1 monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn). This antibody is designed for use in research focused on autoimmune disorders, including myasthenia gravis and thyroid eye disease. Batoclimab's mechanism of action involves modulating the pathway of IgG recycling, potentially altering the autoimmune response. This makes it a valuable tool for studies aimed at understanding and treating conditions mediated by pathogenic autoantibodies.
Synonyms: BAY 1213790
Osocimab (BAY 1213790) is a potent anti-FXIa monoclonal antibody, characterized by a dissociation constant (Ki) of 2.4 nM and a half-maximal effective concentration (EC50) of 0.2 nM. This antibody targets Factor XIa (FXIa), a key enzyme in the coagulation cascade, and its inhibition is associated with a reduced risk of thrombosis. Osocimab effectively inhibits thrombin generation and prolongs the activated partial thromboplastin time (aPTT), demonstrating significant anticoagulant properties. This makes it a valuable tool for studies focused on the regulation of blood coagulation and the development of therapeutic strategies for thrombotic disorders.
Synonyms: ARGX-117
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody that specifically targets complement component C2. By binding to the Sushi-2 domain of C2, Empasiprubar effectively prevents the formation of C3 convertase, thereby inhibiting the activation of both the classical and lectin complement pathways upstream of C3. This inhibition is critical in mitigating the effects of complement-mediated autoimmune disorders, such as autoimmune hemolytic anemia, and in preventing antibody-mediated rejection in organ transplantation. Additionally, Empasiprubar has demonstrated potential in preventing neuroglial and lymphoconjunctival injuries in GM1 antibody-mediated mouse models, suggesting further applications in neuroinflammatory conditions. This antibody offers a promising therapeutic approach by targeting a key point in the complement activation cascade, providing broad utility in research focused on immune regulation and complement system-mediated diseases.
Synonyms: BAY 1093884
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody designed to specifically bind to tissue factor pathway inhibitor (TFPI). This targeted interaction makes Befovacimab an essential tool for research into hemophilia A and B, providing insights into the regulation of the coagulation cascade and potential therapeutic interventions.
Synonyms: Mim8
Denecimig (Mim8) is an innovative bispecific human antibody engineered to mimic activated coagulation factor VIII. It features dual specificity with anti-FIXa and anti-FX arms, effectively enhancing the activation of Factor X. This potent stimulation of FX activation facilitates efficacious hemostasis both in vitro and in vivo, making it a valuable tool for research in coagulation and hemostatic processes.
Synonyms: NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.
